Simiso Sokhela, Willem D F Venter, Bronwyn Bosch, Joana Woods, Kaitlyn McCann, Godspower Akpomiemie, Nomathemba Chandiwana, Nkuli Mashabane, Angela Tembo, Bryony Simmons, Samanta Lalla-Edward, Mark J Siedner, Phumla Sinxadi, Lucas Hermans, Lee Fairlie, Alinda Vos, Elaine Abrams, Jennifer M Manne-Goehler, Michelle Moorhouse, Polly Clayden, Shane Norris, Ambar Qavi, Matthew Chersich, Masebole Masenya, Natasha Arulappan, Andrew Hill
BACKGROUND: ADVANCE compared 3 World Health Organization-recommended first-line regimens in participants with HIV who were antiretroviral naive. METHODS: This randomized, open-label, noninferiority trial enrolled participants living with HIV with no antiretroviral exposure in the previous 6 months to 1 of the following arms: tenofovir alafenamide (TAF) / emtricitabine (FTC) + dolutegravir (DTG) (2 tablets), tenofovir disoproxil fumarate (TDF) / FTC + DTG (2 tablets), or a fixed-dose combination of TDF / FTC / efavirenz (EFV) (1 tablet)...
March 2024: Open Forum Infectious Diseases